



AGM Results

Melbourne, Australia, 30 May 2024 – InhaleRx Ltd (ASX: IRX), (**‘IRX’ or ‘the Company’**) an Australian healthcare company developing unique inhaled drug-device products to address unmet medical needs in the pain management and mental health sectors, advises its 2023 Annual General Meeting (AGM) was held today, 30 May 2024, commencing at 4pm AEST.

All resolutions were put to a poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), details of the resolutions, proxies received in respect of each resolution and poll results are set out in the attached summary.

The Board thanks shareholders for their support and looks forward to providing further updates as it executes its strategy.

Authorised by the Board of Directors.

For further information:

www.inhalerx.com.au

James Barrie, Company Secretary

Phone +61 3 8678 4091

About InhaleRx Limited (ASX: IRX) – www.inhalerx.com.au

InhaleRx Limited is an Australian healthcare company which is developing unique medicinal drug-device products to address unmet medical needs in pain management and mental health sectors.

The overarching goal is to pursue U.S. FDA approval and registration using rapid and cost-effective regulatory pathways, such as 505(b)(2).

There is a significant economic opportunity for IRX and the Company’s shareholders, the first medical indications under investigation and Breakthrough Cancer Pain (BTcP) and Panic Disorder (PD), both of which currently have limited safe and effective treatment options.

IRX holds an innovation patent and provisional patents for the nominated indications and the Company plans to continue to strengthen this position.



In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to the resolutions put to members at the meeting, which were **decided on a Poll**.

	Resolution	Proxy Votes						Poll			Result
		For	Against	Open	Exclusions	Abstain	Total	For	Against	Abstain	Carried / Not Carried
Resolution 1	Adoption of Remuneration Report	34,519,237	34,350	500,000	200,000	-	35,253,587	38,403,698	34,350	-	Carried
		98.48%	0.10%	1.43%				99.91%	0.09%		
Resolution 2	Election of James Barrie as Director	34,753,587	-	500,000	-	-	35,253,587	74,664,367	-	-	Carried
		98.58%	0.00%	1.42%				100.00%	0.00%		
Resolution 3	Re-election of Sean Williams as Director	34,553,587	-	500,000	-	200,000	35,053,587	74,464,367	-	200,000	Carried
		98.57%	0.00%	1.43%				100.00%	0.00%		
Resolution 4	ASX Listing Rule 7.1A Approval of Future Issue of Equity Securities (Special Resolution)	34,738,587	15,000	500,000	-	-	35,253,587	74,649,367	15,000	-	Carried
		98.54%	0.04%	1.42%				99.98%	0.02%		
Resolution 5	Approval of Issue of Incentive Securities to Mr Sean Williams, Director of the Company	34,534,237	19,350	500,000	-	200,000	35,053,587	35,034,237	19,350	39,610,780	Carried
		98.52%	0.06%	1.43%				99.94%	0.06%		
Resolution 6	Approval to Appoint Ingenu CRO Pty Ltd as the Contract Research Organization, a Related Party of the Company	34,753,587	-	500,000	-	-	35,253,587	35,253,587	-	39,410,780	Carried
		98.58%	0.00%	1.42%				100.00%	0.00%		